It is currently trading at $3.15 quite a bit above $2.83, the stock’s 50 day moving average and much lower than the 200 day moving average of $3.54. The 50 day moving average moved up $0.32 whereas the 200 day average was down by -11.12%. Trading was heavy with 340K shares changing hands by the end of trading on Tuesday. Trading volume was up 210.54% over the stocks average daily volume.
Investors are more bullish on shares of Cancer Genetics, Inc. if you take note of the motion in short interest. The stock realized a fall in short interest of -8.92% as of October 13, 2017 from the last reporting period. Short interest decreased from 1,351,806 to 1,231,193 over that period. Days to cover increased 1.0 to 12.0 and the short interest percentage is 0.06% as of October 13.
Cancer Genetics, Inc. (NASDAQ:CGIX) has been the object of insider buying activity recently. Director John Pappajohn purchased 86,185 shares at an average price of $3.26 on Thu the 17th. That brings the Director’s holdings to $8,569,575 per an SEC filing yesterday.
Additionally, here are a few investment firms who have increased or decreased their stake in (CGIX). As of quarter end Eam Investors, LLC had disposed of 11,134 shares trimming its holdings by 9.4%. The value in dollars went from $483,000 to $422,000 decreasing 12.6% quarter over quarter. Ubs Group Ag added to its stake by buying 205,058 shares an increase of 68,352.7% in the quarter. Ubs Group Ag controls 205,358 shares valued at $811,000. The value of the position overall is up by 81,000.0%.
As of the end of the quarter Cutler Group LP had bought a total of 13,200 shares growing its position 2,640.0%. The value of the investment in CGIX increased from $1,000 to $2,000 a change of 100.0% since the last quarter. Bank Of Montreal /can/ trimmed its investment by shedding 2,508 shares a decrease of 17.2% from 06/30/2017 to 09/30/2017. Bank Of Montreal /can/ now holds 12,106 shares worth $33,000. The total value of its holdings decreased 43.1%.
In the latest earnings report the EPS was $-1.02 and is estimated to be $-0.86 for the current year with 19,790,000 shares presently outstanding. Next quarter’s EPS is forecasted at $-0.10 and the next full year EPS is anticipated to be $-0.26.
Cancer Genetics, Inc., launched on April 8, 1999, is involved in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are for three main sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community. Its services include clinical services, biopharma services and discovery services..